RT Journal Article
SR Electronic
T1 Estimating Excess Mortality Following Pediatric and Adolescent Cancer in the U.S.
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.24.20248729
DO 10.1101/2020.12.24.20248729
A1 AnnaLynn M. Williams
A1 Qi Liu
A1 Nickhill Bhakta
A1 Kevin R. Krull
A1 Melissa M. Hudson
A1 Leslie L. Robison
A1 Yutaka Yasui
YR 2020
UL http://medrxiv.org/content/early/2020/12/27/2020.12.24.20248729.abstract
AB The increasing number of long-term survivors of childhood/adolescent cancer are at-risk for premature death resulting from cancer treatment exposures. To better understand the implications of late mortality, we estimated and characterized the magnitude and temporal patterns of annual excess deaths following childhood/adolescent cancers diagnosed in 1975-2016 in the US using SEER 9 registries. We demonstrate for several tumor types that, despite decreasing excess deaths <5.0 years from diagnosis, the total number of excess deaths is not necessarily decreasing due to the growing and aging population of survivors at risk for treatment related late effects.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Cancer Institute at the National Institutes of Health (grant numbers K00CA222742 (A.M.W.), CA21765, Dr. Charlie Roberts, PI) as well as the American Lebanese Syrian Associated Charities (ALSAC).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:SEER data, no IRB oversight neededAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data underlying this article are available US National Cancer Institute’s Surveillance, Epidemiology, and End Results 9-registries which can be accessed at: https://seer.cancer.gov/